Inclusion Criteria:  Is indicated for the treatment of ADHD in children and adolescents 6 to 17 years old, as monotherapy. Must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.  Exclusion Criteria:  Use for participants with a diagnosis other than ADHD. Use for children less than 6 years of age. Use in adults (greater than or equal to [>=] 18 years of age) Prescribed overdose greater than (>) 7 milligram per day (mg/day) for participants > 12 years, or > 4 mg/ day for children lesser than or equal to (<=) 12 years. If monotherapy with Intuniv, no prior treatment with stimulants or atomoxetine.